Caricamento...
Modulation of Autophagy by Sorafenib: Effects on Treatment Response
The multikinase inhibitor sorafenib is, at present, the only drug approved for the treatment of hepatocellular carcinoma (HCC), one of the most lethal types of cancer worldwide. However, the increase in the number of sorafenib tumor resistant cells reduces efficiency. A better knowledge of the intra...
Salvato in:
| Pubblicato in: | Front Pharmacol |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4896953/ https://ncbi.nlm.nih.gov/pubmed/27375485 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00151 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|